PALO ALTO, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Telik, Inc. announced that its 2007 third quarter conference call and webcast will be held on Wednesday, November 7, 2007 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company’s financial results for the third quarter and nine months ended September 30, 2007.
The conference call will be accessible via Telik’s website at http://www.telik.com or by telephone at 888-276-0009 or 612-332-0819. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 893462. The archive will be available from approximately 8:30 p.m. Eastern time on November 7 through November 14, 2007.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidates are TELCYTA(R), a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer; and TELINTRA(R), which is in clinical development for the treatment of myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com
TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications of
Telik, Inc., +1-650-845-7728, cdeguzman@telik.com
Web site: http://www.telik.com/
